ES2517491T3 - Estabilizador de los vasos linfáticos - Google Patents

Estabilizador de los vasos linfáticos Download PDF

Info

Publication number
ES2517491T3
ES2517491T3 ES12181426.3T ES12181426T ES2517491T3 ES 2517491 T3 ES2517491 T3 ES 2517491T3 ES 12181426 T ES12181426 T ES 12181426T ES 2517491 T3 ES2517491 T3 ES 2517491T3
Authority
ES
Spain
Prior art keywords
lymphatic vessels
stabilizer
tie2 activator
prevention
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12181426.3T
Other languages
English (en)
Inventor
Kentaro Kajiya
Masahiro Ota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Application granted granted Critical
Publication of ES2517491T3 publication Critical patent/ES2517491T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Activador de Tie2 para su uso en el tratamiento o prevención de enfermedades de la piel atribuibles a pérdida de linfa causada por inestabilidad estructural de los vasos linfáticos, en el que dicho activador de Tie2 es un extracto de Ginseng Siberiano.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12181426.3T 2008-06-18 2009-06-17 Estabilizador de los vasos linfáticos Active ES2517491T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008159623 2008-06-18
JP2008159623 2008-06-18

Publications (1)

Publication Number Publication Date
ES2517491T3 true ES2517491T3 (es) 2014-11-03

Family

ID=41434153

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09766685.3T Active ES2536418T3 (es) 2008-06-18 2009-06-17 Estabilizador de vasos linfáticos
ES12181426.3T Active ES2517491T3 (es) 2008-06-18 2009-06-17 Estabilizador de los vasos linfáticos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09766685.3T Active ES2536418T3 (es) 2008-06-18 2009-06-17 Estabilizador de vasos linfáticos

Country Status (9)

Country Link
US (1) US8367124B2 (es)
EP (2) EP2319537B1 (es)
JP (2) JP4970594B2 (es)
KR (3) KR20160032272A (es)
CN (2) CN102056630B (es)
ES (2) ES2536418T3 (es)
HK (1) HK1152866A1 (es)
TW (2) TWI495487B (es)
WO (1) WO2009154237A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012101746A1 (ja) * 2011-01-24 2012-08-02 株式会社資生堂 Tie2活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
JP6147954B2 (ja) * 2011-05-10 2017-06-14 丸善製薬株式会社 Ｔｉｅ２活性化剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤
WO2013058579A1 (ko) 2011-10-18 2013-04-25 (주)아모레퍼시픽 시링가레시놀을 포함하는 sirt 1 활성화제
KR102016078B1 (ko) 2012-11-30 2019-08-30 (주)아모레퍼시픽 심장 질환 예방 또는 치료용 조성물
US9440963B2 (en) * 2013-03-15 2016-09-13 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
JP2015199733A (ja) * 2014-04-04 2015-11-12 国立大学法人東北大学 眼圧降下剤
JP6640730B2 (ja) * 2014-10-16 2020-02-05 サントリーホールディングス株式会社 オリーブ果実エキスを含有するＴｉｅ２活性化剤
WO2019098302A1 (ja) * 2017-11-17 2019-05-23 株式会社資生堂 ＶＥ－カドヘリン発現促進剤及び／又はインテグリンα５発現促進剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1070342A (zh) * 1992-08-25 1993-03-31 刘长海 一种含有刺五加和五味子的滋补保健饮料冲剂的制备方法
CN1104113A (zh) * 1994-03-30 1995-06-28 李再胜 冻复灵软膏及其制备方法
JPH08268887A (ja) 1995-02-01 1996-10-15 Suntory Ltd 高血圧症又はそれに起因する医学的症状の予防又は改善剤
JPH10265350A (ja) 1997-03-26 1998-10-06 Shiseido Co Ltd 育毛剤
CN1081926C (zh) * 1997-12-31 2002-04-03 同济医科大学附属同济医院 一种抗肿瘤中药及其制备方法
US6607756B1 (en) 1998-11-09 2003-08-19 Leonie Rosenstiel Method and topical compound for treatment of edema
JP2003221315A (ja) * 2002-01-25 2003-08-05 Kunio Tsuji 育毛用の皮膚外用剤
JP3973912B2 (ja) * 2002-01-25 2007-09-12 邦郎 辻 津液作用を有する生薬のエキス及び血管新生活性を有する生薬エキスからなる育毛用の皮膚外用剤
CN100345553C (zh) * 2003-04-28 2007-10-31 吴光彦 制造刺五加软胶囊的生产工艺
JP4081678B2 (ja) 2003-05-29 2008-04-30 みなべ町 ヘリコバクターピロリの運動能阻害剤
JPWO2005063233A1 (ja) 2003-12-26 2007-07-19 農工大ティー・エル・オー株式会社 肝癌予防及び治療用組成物
KR100855756B1 (ko) * 2006-01-27 2008-09-03 김호연 오가피 추출물을 이용한 가금류 사육방법 및 가금육을사용한 신규한 면류
WO2008059310A1 (en) 2006-11-13 2008-05-22 Avestha Gengraine Technologies Pvt. Ltd Cinnamomum zeylanicum water extracts and their application in diabetes related conditions

Also Published As

Publication number Publication date
TWI532490B (zh) 2016-05-11
TW201233402A (en) 2012-08-16
WO2009154237A1 (ja) 2009-12-23
CN102813689A (zh) 2012-12-12
CN102813689B (zh) 2016-08-10
KR20160032272A (ko) 2016-03-23
US8367124B2 (en) 2013-02-05
US20110091584A1 (en) 2011-04-21
CN102056630B (zh) 2013-03-13
TW201010740A (en) 2010-03-16
EP2526955A1 (en) 2012-11-28
JPWO2009154237A1 (ja) 2011-12-01
JP4970594B2 (ja) 2012-07-11
CN102056630A (zh) 2011-05-11
KR20110027659A (ko) 2011-03-16
KR20160110562A (ko) 2016-09-21
TWI495487B (zh) 2015-08-11
JP5221783B2 (ja) 2013-06-26
EP2319537A4 (en) 2012-02-22
ES2536418T3 (es) 2015-05-25
HK1152866A1 (en) 2012-03-16
JP2012107041A (ja) 2012-06-07
EP2319537B1 (en) 2015-04-29
EP2319537A1 (en) 2011-05-11
KR101784645B1 (ko) 2017-10-11
EP2526955B1 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
ES2517491T3 (es) Estabilizador de los vasos linfáticos
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
AR113211A2 (es) Derivados de bencilfenilciclohexano y métodos de uso
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
DOP2011000084A (es) Uso de ditiina-tetracarboximidas para combatir hongos fitopatogenos
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
BR112013000537A2 (pt) composição aquosa contendo bromexina
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
ES2666397T3 (es) Activación de CD89 en terapia
CO6351777A2 (es) Compuestos de tetraciclina sustituidod con fluor en c7
AR088622A1 (es) 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
ES2531516T3 (es) Uso de escina
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
CL2011002617A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros.
ES2528366T3 (es) Citicolina para el tratamiento del glaucoma
UY29417A1 (es) Agentes endoparasiticidas